{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:01:55Z","timestamp":1793505715845,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40256-023-00615-3","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T14:02:05Z","timestamp":1697724125000},"page":"103-115","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Intravenous Diltiazem Versus Metoprolol in Acute Rate Control of Atrial Fibrillation\/Flutter and Rapid Ventricular Response: A Meta-Analysis of Randomized and Observational Studies"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7965-1858","authenticated-orcid":false,"given":"Alexander","family":"Bolton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3381-3529","authenticated-orcid":false,"given":"Bishow","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Adhaduk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3181-777X","authenticated-orcid":false,"given":"Mohammed","family":"Alsuhaibani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-1018","authenticated-orcid":false,"given":"Riley","family":"Samuelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3604-0093","authenticated-orcid":false,"given":"Marin L.","family":"Schweizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6875-1367","authenticated-orcid":false,"given":"Denice","family":"Hodgson-Zingman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"issue":"8","key":"615_CR1","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.amjcard.2013.05.063","volume":"112","author":"S Colilla","year":"2013","unstructured":"Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2013.05.063.","journal-title":"Am J Cardiol"},{"issue":"14","key":"615_CR2","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/CIRCULATIONAHA.110.009035","volume":"123","author":"RR Huxley","year":"2011","unstructured":"Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loehr LR, Soliman EZ, Maclehose R, Konety S, Alonso A. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011;123(14):1501\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.009035.","journal-title":"Circulation"},{"issue":"5","key":"615_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/s0002-9343(02)01253-6","volume":"113","author":"H Vidaillet","year":"2002","unstructured":"Vidaillet H, Granada JF, Chyou P, Maassen K, Ortiz M, Pulido JN, Sharma P, Smith PN, Hayes J. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med. 2002;113(5):365\u201370. https:\/\/doi.org\/10.1016\/s0002-9343(02)01253-6.","journal-title":"Am J Med"},{"key":"615_CR4","doi-asserted-by":"publisher","unstructured":"January CT, Wann LS, Alpert JS, et al.; ACC\/AHA Task Force Members. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):e199\u2013267. https:\/\/doi.org\/10.1161\/CIR.0000000000000041.","DOI":"10.1161\/CIR.0000000000000041"},{"key":"615_CR5","doi-asserted-by":"publisher","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.019.","DOI":"10.1016\/j.jacc.2013.05.019"},{"key":"615_CR6","doi-asserted-by":"publisher","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u2013W64. https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00135","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"615_CR7","doi-asserted-by":"publisher","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-12. https:\/\/doi.org\/10.1001\/jama.283.15.2008.","DOI":"10.1001\/jama.283.15.2008"},{"key":"615_CR8","unstructured":"Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm. Accessed 27 Feb 2021."},{"key":"615_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"615_CR10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"key":"615_CR11","unstructured":"Review Manager (RevMan)[Computer Program]. Version 5.1. Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2011."},{"key":"615_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ajem.2022.10.001","volume":"62","author":"CT Compagner","year":"2022","unstructured":"Compagner CT, Wysocki CR, Reich EK, Zimmerman LH, Holzhausen JM. Intravenous metoprolol versus diltiazem for atrial fibrillation with concomitant heart failure. Am J Emerg Med. 2022;62:49\u201354. https:\/\/doi.org\/10.1016\/j.ajem.2022.10.001.","journal-title":"Am J Emerg Med"},{"issue":"6","key":"615_CR13","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1136\/emj.2003.012047","volume":"22","author":"C Demircan","year":"2005","unstructured":"Demircan C, Cikriklar HI, Engindeniz Z, Cebicci H, Atar N, Guler V, Unlu EO, Ozdemir B. Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation. Emerg Med J. 2005;22(6):411\u20134. https:\/\/doi.org\/10.1136\/emj.2003.012047.","journal-title":"Emerg Med J"},{"issue":"10","key":"615_CR14","first-page":"1805","volume":"18","author":"HY Diao","year":"2009","unstructured":"Diao HY, Liu B, Chen HB, Shi YF, Wang LJ. Comparison of the effectiveness of intravenous diltiazem and metoprolol in controlling the rapid ventricular rate in patients with atrial fibrillation. Chin J Emerg Med. 2009;18(10):1805\u20137.","journal-title":"Chin J Emerg Med."},{"issue":"2","key":"615_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jemermed.2015.01.014","volume":"49","author":"C Fromm","year":"2015","unstructured":"Fromm C, Suau SJ, Cohen V, Likourezos A, Jellinek-Cohen S, Rose J, Marshall J. Diltiazem vs. metoprolol in the management of atrial fibrillation or flutter with rapid ventricular rate in the emergency department. J Emerg Med. 2015;49(2):175\u201382. https:\/\/doi.org\/10.1016\/j.jemermed.2015.01.014.","journal-title":"J Emerg Med"},{"key":"615_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ajem.2022.03.058","volume":"58","author":"M Hasbrouck","year":"2022","unstructured":"Hasbrouck M, Nguyen TT. Acute management of atrial fibrillation in congestive heart failure with reduced ejection fraction in the emergency department. Am J Emerg Med. 2022;58:39\u201342. https:\/\/doi.org\/10.1016\/j.ajem.2022.03.058.","journal-title":"Am J Emerg Med"},{"issue":"24","key":"615_CR17","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.2146\/ajhp160126","volume":"73","author":"MC Hines","year":"2016","unstructured":"Hines MC, Reed BN, Ivaturi V, Bontempo LJ, Bond MC, Hayes BD. Diltiazem versus metoprolol for rate control in atrial fibrillation with rapid ventricular response in the emergency department. Am J Health Syst Pharm. 2016;73(24):2068\u201376. https:\/\/doi.org\/10.2146\/ajhp160126.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"615_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajem.2018.04.062","volume":"37","author":"R Hirschy","year":"2019","unstructured":"Hirschy R, Ackerbauer KA, Peksa GD, O\u2019Donnell EP, DeMott JM. Metoprolol vs. diltiazem in the acute management of atrial fibrillation in patients with heart failure with reduced ejection fraction. Am J Emerg Med. 2019;37(1):80\u20134. https:\/\/doi.org\/10.1016\/j.ajem.2018.04.062.","journal-title":"Am J Emerg Med"},{"issue":"9","key":"615_CR19","first-page":"4556","volume":"8","author":"XM Kong","year":"2008","unstructured":"Kong XM. Efficacy of intravenous diltiazem and metoprolol in the treatment of atrial fibrillation with rapid ventricular rate. Chin J Misdiagn. 2008;8(9):4556\u20137.","journal-title":"Chin J Misdiagn."},{"issue":"1","key":"615_CR20","first-page":"69","volume":"16","author":"B Lin","year":"2007","unstructured":"Lin B, Zhang Y, Dai HY. Therapeutic efficacy of metoprolol and diltiazem on the treatment of rapid atrial fibrillation. Chin J Cardiovasc Rehabil Med. 2007;16(1):69\u201371.","journal-title":"Chin J Cardiovasc Rehabil Med."},{"issue":"20","key":"615_CR21","doi-asserted-by":"publisher","first-page":"31063","DOI":"10.1016\/j.ajem.2020.11.039","volume":"S0735\u20136757","author":"P McGrath","year":"2020","unstructured":"McGrath P, Kersten B, Chilbert MR, Rusch C, Nadler M. Evaluation of metoprolol versus diltiazem for rate control of atrial fibrillation in the emergency department. Am J Emerg Med. 2020;S0735\u20136757(20):31063\u20139. https:\/\/doi.org\/10.1016\/j.ajem.2020.11.039.","journal-title":"Am J Emerg Med"},{"issue":"9","key":"615_CR22","doi-asserted-by":"publisher","first-page":"205031212110177","DOI":"10.1177\/20503121211017756","volume":"25","author":"T Medeiros","year":"2021","unstructured":"Medeiros T, Bui V, Almekdash MH, Keesari R, Lee YR. Rate control with intravenous diltiazem, verapamil, and metoprolol in acute atrial fibrillation with rapid ventricular rate. SAGE Open Med. 2021;25(9):20503121211017756. https:\/\/doi.org\/10.1177\/20503121211017756.","journal-title":"SAGE Open Med."},{"issue":"1","key":"615_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.28982\/josam.443209","volume":"3","author":"MB Memis","year":"2019","unstructured":"Memis MB, Ak R, Ozturk TC, Onur O, Ordu O. Which one is the first choice for rapid ventricular rate atrial fibrillation in emergency department: metoprolol or diltiazem? A randomized clinical trial. J Surg Med. 2019;3(1):13\u20137. https:\/\/doi.org\/10.28982\/josam.443209.","journal-title":"J Surg Med."},{"issue":"4","key":"615_CR24","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/SHK.0000000000000869","volume":"48","author":"A Moskowitz","year":"2017","unstructured":"Moskowitz A, Chen KP, Cooper AZ, Chahin A, Ghassemi MM, Celi LA. Management of atrial fibrillation with rapid ventricular response in the intensive care unit: a secondary analysis of electronic health record data. Shock. 2017;48(4):436\u201340. https:\/\/doi.org\/10.1097\/SHK.0000000000000869.","journal-title":"Shock"},{"key":"615_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2020.10.003","author":"S Nu\u00f1ez Cruz","year":"2020","unstructured":"Nu\u00f1ez Cruz S, DeMott JM, Peksa GD, Slocum GW. Evaluation of the blood pressure effects of diltiazem versus metoprolol in the acute treatment of atrial fibrillation with rapid ventricular rate. Am J Emerg Med. 2020. https:\/\/doi.org\/10.1016\/j.ajem.2020.10.003.","journal-title":"Am J Emerg Med"},{"issue":"8","key":"615_CR26","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1177\/10600280211056356","volume":"56","author":"SQ Xiao","year":"2022","unstructured":"Xiao SQ, Ibarra F Jr, Cruz M. Intravenous metoprolol versus diltiazem for rate control in atrial fibrillation. Ann Pharmacother. 2022;56(8):916\u201321. https:\/\/doi.org\/10.1177\/10600280211056356.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"615_CR27","first-page":"206","volume":"16","author":"SG Zhong","year":"2010","unstructured":"Zhong SG, Chen AW, Peng N. Contrasting the effectiveness of metoprolol and diltiazem in rapid atrial fibrillation just by intravenous injection. Int Med Health Guid News. 2010;16(2):206\u20138.","journal-title":"Int Med Health Guid News."},{"key":"615_CR28","unstructured":"Diltiazem: Drug information.\u00a0UpToDate. Retrieved March 2, 2022, from https:\/\/www-uptodate-com.proxy.lib.uiowa.edu\/contents\/diltiazem-drug-information."},{"key":"615_CR29","unstructured":"Metoprolol: Drug information.\u00a0UpToDate. Retrieved March 2, 2022, from\u00a0https:\/\/www-uptodate-com.proxy.lib.uiowa.edu\/contents\/metoprolol-drug-information."},{"issue":"3","key":"615_CR30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/MEJ.0000000000000227","volume":"22","author":"JL Martingale","year":"2015","unstructured":"Martingale JL, de Souza IS, Silverberg M, Freedman J, Sinert R. Beta-Blockers versus calcium channel blockers for acute rate control of atrial fibrillation with rapid ventricular response: a systematic review. Eur J Emerg Med. 2015;22(3):150\u20134. https:\/\/doi.org\/10.1097\/MEJ.0000000000000227.","journal-title":"Eur J Emerg Med"},{"key":"615_CR31","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.ajem.2021.06.053","volume":"48","author":"SH Jafri","year":"2021","unstructured":"Jafri SH, Xu J, Warsi I, Cerecedo-Lopez CD. Diltiazem versus metoprolol for the management of atrial fibrillation: a systematic review and meta-analysis. Am J Emerg Med. 2021;48:323\u20137. https:\/\/doi.org\/10.1016\/j.ajem.2021.06.053.","journal-title":"Am J Emerg Med"},{"key":"615_CR32","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ajem.2021.08.082","volume":"51","author":"Q Lan","year":"2022","unstructured":"Lan Q, Wu F, Han B, Ma L, Han J, Yao Y. Intravenous diltiazem versus metoprolol for atrial fibrillation with rapid ventricular rate: a meta-analysis. Am J Emerg Med. 2022;51:248\u201356. https:\/\/doi.org\/10.1016\/j.ajem.2021.08.082.","journal-title":"Am J Emerg Med"},{"issue":"6","key":"615_CR33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ihj.2022.10.195","volume":"74","author":"SC Sharda","year":"2022","unstructured":"Sharda SC, Bhatia MS. Comparison of diltiazem and metoprolol for atrial fibrillation with rapid ventricular rate: Systematic review and meta-analysis. Indian Heart J. 2022;74(6):494\u20139. https:\/\/doi.org\/10.1016\/j.ihj.2022.10.195.","journal-title":"Indian Heart J"},{"issue":"4","key":"615_CR34","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.chest.2020.10.049","volume":"159","author":"NA Bosch","year":"2021","unstructured":"Bosch NA, Rucci JM, Massaro JM, Winter MR, Quinn EK, Chon KH, McManus DD, Walkey AJ. Comparative effectiveness of heart rate control medications for the treatment of sepsis-associated atrial fibrillation. Chest. 2021;159(4):1452\u20139. https:\/\/doi.org\/10.1016\/j.chest.2020.10.049.","journal-title":"Chest"},{"issue":"5","key":"615_CR35","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jacc.2019.04.067","volume":"74","author":"P Joseph","year":"2019","unstructured":"Joseph P, Swedberg K, Leong DP, Yusuf S. The evolution of \u03b2-blockers in coronary artery disease and heart failure (Part 1\/5). J Am Coll Cardiol. 2019;74(5):672\u201382. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.067.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"615_CR36","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1056\/NEJM198808183190701","volume":"319","author":"Multicenter Diltiazem Postinfarction Trial Research Group","year":"1988","unstructured":"Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988;319(7):385\u201392. https:\/\/doi.org\/10.1056\/NEJM198808183190701.","journal-title":"N Engl J Med"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00615-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-023-00615-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-023-00615-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T12:30:45Z","timestamp":1706013045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-023-00615-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["615"],"URL":"https:\/\/doi.org\/10.1007\/s40256-023-00615-3","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"assertion":[{"value":"28 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received to conduct the analysis described in the manuscript, nor to assist in the preparation of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Marin Schweizer reports that she receives payment from 3M (Saint Paul, MN) for speaking on their behalf on infectious disease products. Otherwise, the other remaining authors of this manuscript (Alexander Bolton, Bishow Paudel, Mehul Adhaduk, Mohammed Alsuhaibani, Riley Samuelson, and Denice Hodgson-Zingman) declare that they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No further data is available.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Alexander Bolton: Conceptualization, methodology, formal analysis, investigation, and writing\u2014original draft; Bishow Paudel: methodology, investigation, and writing\u2014review and editing; Mehul Adhaduk: validation and writing\u2014review and editing; Mohammed Alsuhaibani: validation and writing\u2014review and editing; Riley Samuelson: methodology and writing\u2014original draft; Marin Schweizer: methodology, writing\u2014review and editing, and supervision; Denice Hodgson-Zingman: writing\u2014review and editing and supervision.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}